Incidence of Major Cardiovascular Events in Diabetic Patients With ACS Undergoing Coronary Angioplasty and Treated With Clopidogrel 150 mg Versus 75 mg
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 167 participants.
Also called NCT03329261
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 167 participants
- Sponsor
- Laboratoires Teriak
- Registry
-
NCT03329261
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Tunisia
- Registry status
- Completed
Technical summary
Registry record NCT03329261. Randomized; no masking; primary purpose treatment. Start 2017-12-07 (actual); primary completion 2019-03-24 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Incidence of Major Cardiovascular Events in Diabetic Patients With ACS Undergoing Coronary Angioplasty and Treated With Clopidogrel 150 mg Versus 75 mg
- Acronym
- IDASCOP 1
- Condition
- Diabetes Mellitus, Type 2
- Condition
- NSTEMI - Non-ST Segment Elevation MI
- Condition
- Coronary Angioplasty
- Intervention (Drug)
- Clopidogrel
- Lead sponsor
- Laboratoires Teriak
Record details
- Record id
cardio:ct-nct03329261- Content hash
39d85dc951a1744f757147561149800ed45d9652055615261262b3d656e2c7de